Trial Information

Summary: Treatment of Preclinical Hypertrophic Cardiomyopathy with Diltiazem

Researchers at Brigham and Women’s Hospital in Boston, MA are currently enrolling participants for a research study of Hypertrophic Cardiomyopathy (HCM). HCM is an inherited heart disorder affecting 1 in 1000 individuals. People with HCM have unexplained thickening of the heart wall called left ventricular hypertrophy (LVH). HCM is caused by mutations in genes involved in the heart’s ability to contract and relax. You qualify for this research study if you are known to carry a gene mutation that puts you at risk for developing HCM but do not currently have any clinical signs of HCM. The study is interested in learning whether a medication called diltiazem can be used to treat and prevent the progression of HCM. Diltiazem is FDA approved to treat hypertension but its use for HCM is experimental. The study will last for five years and includes taking a pill (Diltiazem or inactive sugar pill) once a day for the first four years. Participants will be asked to come to the hospital for a total of 13 study visits in five years (four years while taking the study drug and one year after for follow-up).

To learn more about the study, please contact Allison L. Cirino, MS, CGC at 617-732-7921 or acirino@partners.org.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.